Hiro

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

Retrieved on: 
Thursday, February 15, 2024

Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.

Key Points: 
  • Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.
  • The TaRGET trial is a critical first step in evaluating this potential."
  • This scarring increases the risk of dangerously fast heart rhythms that can lead to sudden cardiac death (SCD).
  • An implantable cardioverter defibrillator (ICD) is recommended for prevention of SCD for ACM patients considered at high risk for SCD.

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

Retrieved on: 
Thursday, February 15, 2024

Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.

Key Points: 
  • Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.
  • The TaRGET trial is a critical first step in evaluating this potential."
  • This scarring increases the risk of dangerously fast heart rhythms that can lead to sudden cardiac death (SCD).
  • An implantable cardioverter defibrillator (ICD) is recommended for prevention of SCD for ACM patients considered at high risk for SCD.

Generational Equity Advises Courante Oncology in its Sale to Harvest Integrated Research Organization

Retrieved on: 
Friday, September 1, 2023

Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce that its client, Courante Oncology, Inc., has been acquired by Harvest Integrated Research Organization.

Key Points: 
  • Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce that its client, Courante Oncology, Inc., has been acquired by Harvest Integrated Research Organization.
  • Located in Excelsior, Minnesota, Courante Oncology (Courante) is a full-service clinical research provider specializing in oncology product development.
  • The acquisition by Harvest Integrated Research Organization (HiRO) recognizes the oncology expertise and dedication of the Courante team, and HiRO is excited to expand their global service offerings and functions further into the U.S. and beyond.
  • They have unparalleled experience in oncology and the passion they have for exploring new oncology treatments for patients has really shined through during this process.

MSCI appoints Hiromichi Mizuno as a Special Advisor to the CEO

Retrieved on: 
Tuesday, August 1, 2023

MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, is pleased to announce the appointment of Hiromichi (Hiro) Mizuno as a Special Advisor to the CEO, effective August 1, 2023.

Key Points: 
  • MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, is pleased to announce the appointment of Hiromichi (Hiro) Mizuno as a Special Advisor to the CEO, effective August 1, 2023.
  • He is particularly known for his impact and active efforts in advocating for and addressing climate change and gender diversity through investment practices.
  • “We are thrilled to welcome Hiro Mizuno to MSCI,” said Henry Fernandez, Chairman and Chief Executive Officer of MSCI.
  • “It is a privilege to join forces with MSCI at this transformative and challenging time for the investment industry,” said Hiro Mizuno.

The 2023 Ogawa-Yamanaka Stem Cell Prize Awarded to Magdalena Zernicka-Goetz

Retrieved on: 
Tuesday, June 27, 2023

SAN FRANCISCO, June 27, 2023 /PRNewswire/ -- Magdalena Zernicka-Goetz, PhD, was announced today as the recipient of the 2023 Ogawa-Yamanaka Stem Cell Prize by Gladstone Institutes. Zernicka-Goetz is a professor of mammalian development and stem cell biology in the Department of Physiology, Development, and Neuroscience at the University of Cambridge, as well as the Bren Professor of Biology and Biological Engineering at the California Institute of Technology.

Key Points: 
  • SAN FRANCISCO, June 27, 2023 /PRNewswire/ -- Magdalena Zernicka-Goetz, PhD, was announced today as the recipient of the 2023 Ogawa-Yamanaka Stem Cell Prize by Gladstone Institutes.
  • Established in 2015 by a generous gift from the Hiro and Betty Ogawa family, the Ogawa-Yamanaka Stem Cell Prize honors scientists conducting groundbreaking work in translational regenerative medicine using reprogrammed cells.
  • "I am deeply honored to receive the Ogawa-Yamanaka Stem Cell Prize for my work," Zernicka-Goetz says.
  • Zernicka-Goetz was selected for the 2023 Ogawa-Yamanaka Stem Cell Prize by an independent committee of international stem cell experts from a highly competitive pool of nominees.

LiveWire Group, Inc. appoints Hiromichi Mizuno to Board of Directors

Retrieved on: 
Thursday, June 8, 2023

LiveWire Group, Inc. (“LiveWire”) (NYSE: LVWR) today announced the appointment of Mr. Hiromichi (Hiro) Mizuno to the Company's Board of Directors, effective June 12, 2023.

Key Points: 
  • LiveWire Group, Inc. (“LiveWire”) (NYSE: LVWR) today announced the appointment of Mr. Hiromichi (Hiro) Mizuno to the Company's Board of Directors, effective June 12, 2023.
  • He previously served as Executive Managing Director and Chief Investment Officer of Government Pension Investment Fund of Japan (GPIF), the largest pension fund in the world.
  • Additionally, Mizuno has served as a non-Executive board member of Tesla, Inc. and serves as a Mission Committee Member at Danone, S.A.
    Mizuno holds an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.
  • Additionally, Paul Krause, Chief Legal Officer at Harley-Davidson will also be appointed to the Board of Directors of LiveWire Group, Inc. effective June 12, 2023.

AWARD-WINNING HIRO® SAKE ANNOUNCES THE DEBUT OF HIRO SAKETINI READY-TO-DRINK COCKTAIL

Retrieved on: 
Tuesday, December 6, 2022

MIAMI, Dec. 6, 2022 /PRNewswire/ -- Hiro Sake®, the award-winning, handcrafted, premium sake from Japan, is proud to announce the introduction of HIRO SAKETINI, the brand's first Ready-To-Drink canned saketini cocktail and the first saketini RTD in the US market. Hiro Saketini will debut with a Black Cherry and a Watermelon Saketini in Florida this month at on-premise accounts initially, following to the off-premise market. In Florida, Hiro has named Breakthru Beverage Group as their distributor partner for Hiro Saketini. Distribution and additional flavors will expand across the U.S. in 2023.

Key Points: 
  • Debut of Hiro Saketini Ready-to-Drink Cocktail, the first saketini RTD in US market.
  • "When we launched Hiro Sake in 2011 we were hopeful that the U.S. market for sake would grow, develop and mature and it did," says Carlos Arana, Hiro Sake co-founder and CEO.
  • The Hiro Saketini is made with imported Japanese Hiro Sake Red, a junmai sake brewed in Japan, which is blended with natural fruit flavorings and carbonated water.
  • In other Hiro Sake news, the brand was originally launched in 2011 with the award winning Hiro Red a junmai sake, Hiro Blue a junmai ginjo sake and in 2016 introduced ultra-premium Hiro Gold a junmai daiginjo sake.

17LIVE Group CEO Hirofumi Ono Steps Down

Retrieved on: 
Thursday, September 1, 2022

TAIPEI, Taiwan, Sept. 1, 2022 /PRNewswire/ -- 17LIVE, Inc. announced today that Hirofumi Ono ("Hiro") has stepped down as Group CEO of 17LIVE Group. Alex Lien ("Alex") has been promoted to Group COO to lead the company. The current Group COO Jing Shen Ng ("JS") will turn his focus to product and development as Group CTO.

Key Points: 
  • Alex Lien Takes Over the Leadership as New Group COO; Jing Shen Ng Appointed Group CTO
    TAIPEI, Taiwan, Sept. 1, 2022 /PRNewswire/ -- 17LIVE, Inc. announced today that Hirofumi Ono ("Hiro") has stepped down as Group CEO of 17LIVE Group.
  • The current Group COO Jing Shen Ng ("JS") will turn his focus to product and development as Group CTO.
  • I believe that Alex's appointment as Group COO will allow JS, who has been leading us as the Group COO, to focus on our products."
  • "17LIVE Group will continue to be responsive to market changes," said Alex.

Oncology Research Veterans Launch TrialNAV - An Innovative Clinical Research Solutions Company

Retrieved on: 
Wednesday, June 8, 2022

PHOENIX, June 8, 2022 /PRNewswire/ -- TrialNAV, an innovative clinical research solutions company designed to bridge the gaps between industry sponsors, research sites, and cancer trial participants today announced its launch. The company's suite of expansive offerings will empower its clients with a complete solution for the identified challenges in the pharmaceutical and technology industries, clinical research organizations, site management organizations, and clinical research sites within healthcare organizations. The solutions are designed to improve enrollment in clinical research and provide better access to treatment options for people living with cancer.

Key Points: 
  • The solutions are designed to improve enrollment in clinical research and provide better access to treatment options for people living with cancer.
  • For research sites, TrialNAV develops program architecture with an emphasis on efficiency in feasibility, portfolio management, staffing solutions, digital transformation, decentralized clinical trials, and multicenter trial management.
  • Leading TrialNAV are highly experienced cancer research professionals, co-founders and co-CEOs, Tandy Tipps, M.ED, M.P.A., PH.D. and Brenda Noggy, RN, BSN, CCRP.
  • Dr. Tipps have more than 25 years of experience leading global oncology clinical research initiatives and developing global research site networks.

SMBC Welcomes Hirofumi Otsuka as New Chief Executive Officer of SMBC Americas Division and President and CEO of SMBC Americas Holdings

Retrieved on: 
Tuesday, April 19, 2022

SMBC, a member of SMBC Group, announced today that Hirofumi (Hiro) Otsuka will assume the positions of Chief Executive Officer of SMBC Americas Division and President and CEO of SMBC Americas Holdings, Inc. (SMBCAH) from Hiro Hyakutome, who served in these roles since April 2019.

Key Points: 
  • SMBC, a member of SMBC Group, announced today that Hirofumi (Hiro) Otsuka will assume the positions of Chief Executive Officer of SMBC Americas Division and President and CEO of SMBC Americas Holdings, Inc. (SMBCAH) from Hiro Hyakutome, who served in these roles since April 2019.
  • Mr. Hyakutomes new assignment is Senior Managing Executive Officer and Group Chief Compliance Officer for SMBC Group in Tokyo.
  • Mr. Otsuka brings a wealth of experience to the Americas from his 32 years at SMBC in various senior-level staff and line capacities, including a decade in the Americas.
  • I also congratulate Mr. Otsuka as we strive to realize even greater promise and opportunity in the Americas.